

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A method of inducing, in a human, serum antibodies which protect against infection with *S. typhi*, comprising administering to said human, a composition comprising a molecular conjugate of the *S. typhi* Vi polysaccharide comprising an N-acetyl group and covalently bound through a carboxylic acid dihydrazide linker to *Pseudomonas aeruginosa* recombinant exoprotein A in a pharmaceutically acceptable carrier.

Claim 2 (canceled)

²
Claim ~~2~~ (previously presented): The method of claim 1 wherein said conjugate molecule is administered at a dose of about 3 micrograms to about 50 micrograms of *S. typhi* Vi polysaccharide.

³
Claim ~~4~~ (original): The method of claim 3 wherein said conjugate molecule is administered at a dose of about 25 micrograms of Vi polysaccharide.

⁴
Claim ~~5~~ (previously amended): The method of claim 1 wherein the antibodies protect the human against infection by *S. typhi*.

Claims 6-11 (canceled)

¹⁰
Claim ~~12~~ (currently amended): A method for vaccinating a human against *S. typhi* infection, comprising administering to the human an immunizing amount of a composition comprising a molecular conjugate of *S. typhi* Vi polysaccharide comprising an N-acetyl group and covalently bound through a carboxylic dihydrazide linker of *Pseudomonas aeruginosa* recombinant exoprotein A in a pharmaceutically acceptable carrier[[],].

Claim 13 (canceled)

Allowance

¹⁶
Claim ~~14~~ (previously presented): A vaccine composition comprising an immunologically effective amount of a molecular conjugate of *S. typhi* Vi polysaccharide comprising an N-acetyl group and covalently bound through a carboxylic acid dihydrazide linker to *Pseudomonas aeruginosa* recombinant exoprotein A, in a pharmaceutically acceptable carrier.

Claim 15 (canceled)

⁵
Claim ~~16~~ (original): The method of claim ~~5~~ wherein the human is a 2 to 3 year old.

⁶
Claim ~~17~~ (original): The method of claim ~~5~~ wherein the human is a 4 to 5 year old.

⁷
Claim ~~18~~ (original): The method of claim ~~5~~ wherein the human is a 5 to 17 year old.

⁸
Claim ~~19~~ (original): The method of claim ~~5~~ wherein the human is an adult.

¹¹
Claim ~~20~~ (original): The method of claim ~~12~~ wherein the human is a 2 to 3 year old.

¹²
Claim ~~21~~ (original): The method of claim ~~12~~ wherein the human is a 4 to 5 year old.

¹³
Claim ~~22~~ (original): The method of claim ~~12~~ wherein the human is a 5 to 14 year old.

¹⁴
Claim ~~23~~ (original): The method of claim ~~12~~ wherein the human is an adult.

⁹
Claim ~~24~~ (previously presented): The method of claim 1 wherein said Vi polysaccharide is covalently bound to the rEPA by means of an adipic acid dihydrazide linker.

¹⁵
Claim ~~25~~ (previously presented): The method of claim ~~12~~ wherein the *S. typhi* Vi polysaccharide is covalently bound to the *Pseudomonas aeruginosa* recombinant exoprotein A by means of an adipic acid dihydrazide linker.

Claim ~~26~~¹⁷ (previously presented): The vaccine composition of claim ~~14~~¹⁶ wherein the *S. typhi* Vi polysaccharide is covalently bound to the *Pseudomonas aeruginosa* recombinant exoprotein A by means of an adipic acid dihydrazide linker.

Claim ~~27~~¹⁸ (new): The vaccine composition of claim ~~14~~¹⁶, wherein the vaccine composition is a human vaccine composition.

Claim ~~28~~¹⁹ (new): The vaccine composition of claim ~~26~~¹⁷, wherein the vaccine composition is a human vaccine composition.